EGFR and hepatocellular carcinoma: A549 cells (KRAS-G12D mutation, P53 wide-type), NCI-H2228 (EML4-ALK variant 3, P53 Q331* mutation) and HCC-827 (EGFR exon19 deletion mutant, inactivation P53 mutation) used in the current study contain rearrangements of chromosomes and substantial changes in the genomic landscape.